Is Cannabis Stock Aurora Cannabis (ACB) a Buy?

: ACB | Aurora Cannabis Inc. Common Shares News, Ratings, and Charts

ACB – This week started off with the cannabis sector plunging into the red with double-digit losses for many large-cap stocks. Aurora Cannabis was among one of the biggest decliners in the market. .

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

This week started off with the cannabis sector plunging into the red with double-digit losses for many large-cap stocks. Aurora Cannabis was among one of the biggest decliners in the market. 

Last week Aurora Cannabis announced that it had provided notice to all holders of the company’s CAD$230 million 5% unsecured, convertible debentures (which are due March 9, 2020), that they have an opportunity to voluntarily convert their debentures at the Amended Early Conversion Ratio. So what does this actually mean?

In simple terms, this means that anyone who held debentures had the option to convert them into common shares on Monday, November 18, 2019.  They will determine the amended early conversion ratio by giving a 6% discount to the VWAP (volume-weighted average selling price). By doing this, it causes further dilution of Aurora Cannabis’ share price. 

This is a significant factor that drove Aurora Cannabis down so drastically but there was also other negative news that hit the headlines. On Monday it was announced that the Shall Law Firm and the Rosen Law Firm have both announced Investigations of Securities Claims Against Aurora Cannabis. They are encouraging investors with losses of over $100,000 to contact the firm. 

Despite this unfavorable news, two analysts recently voiced their positive opinions about Aurora Cannabis which is why, as investors, we should not lose track of our long term perspective. 

Cantor Fitzgerald analyst Pablo Zuanic actually upgraded the stock last week upgraded to overweight from neutral while raising his price target to $5.85 from $5.10. His reasons for the upgrade are as follows: “We do not expect a worse quarter for the group” Aurora looks as if it’s in better shape than its competitors, the company shows a strong understanding of the market, and the updates announced Thursday afternoon were “more decisive actions” than rivals are making. It seems as if Aurora Cannabis is committed to survival during these tou times which many companies may have a hard time doing. Pablo also stated “Kudos for the timeliness and depth of disclosure (best in class among the larger LPs.” “We think this should account for something.”

Another positive note from Cowen analyst Vivian Azer stated that, “We now have cash, it’s a good thing,” even as she dropped her price target to $6 from $8. “With the Canadian cannabis sector under-whelming across the board, for one reason or another, ACB delivered on perhaps the most critical element: more cash,” stated Azer, who maintains an outperform rating. “In our view, management is taking a prudent approach to match up supply capacity with demand, thus slowing down capital spending. Given its low-cost production, ACB seems prepared to leverage its scale advantages.

We will be watching to see how Aurora Cannabis performs after the early conversion period for their debentures ends Wednesday, November 20th. The stock has taken an absolute beating in a short period of time which could indicate that a bounce could be coming, but we are not in the business of catching falling knives. 

Aurora Cannabis remains one of our favorite cannabis companies but we are exercising extreme caution when entering the markets at this time.  Waiting until the dust settles could be a great strategy to deploy during this volatility. 

(Disclosure: The author owns shares of Aurora Cannabis)


ACB shares were unchanged in after-hours trading Tuesday. Year-to-date, ACB has declined -52.82%, versus a 26.55% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating
CGCGet RatingGet RatingGet Rating
GWPHGet RatingGet RatingGet Rating
CRONGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating
TLRYGet RatingGet RatingGet Rating
CTSTGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Top Stories on StockNews.com

NASDAQ: MSFT | Microsoft Corporation News, Ratings, and Charts

Microsoft And Apple Continue to Thrive

Microsoft (MSFT) and Apple’s (AAPL) are both worth over $1.5 Trillion.
: Z | Zillow Group Inc. Cl C News, Ratings, and Charts

Chart of the Day: Zillow Group (Z)

Zillow Group (Z) has tested its channel trendlines multiple times.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Is This “REALLY” a Bull Market?

Few people have pounded the table harder that this is a bear market. Yet the size and length of this rally for the S&P (SPY) does make one contemplate all the possibilities. Read on for a detailed review of where we stand now and what is likely next for stocks.
NYSE: TSM | Taiwan Semiconductor Manufacturing Company Ltd. News, Ratings, and Charts

3 Semiconductor Stocks Set To Rise

The shift to remote work has resulted in increased demand for semiconductors. Taiwan Semiconductor (TSM), ASML (ASML), and Broadcom (AVGO are set to soar.
NASDAQ: AMGN | Amgen Inc. News, Ratings, and Charts

3 Top Biotech Stocks for July

The biotech sector is one of the obvious winners of the coronavirus. Amgen (AMGN), Vertex (VRTX), and Seattle Genetics (SGEN) are the top stock picks for July.

Read More Stories


More Aurora Cannabis Inc. Common Shares (ACB) News View All

Event/DateSymbolNews DetailStart PriceEnd PriceChangePOWR Rating
Loading, please wait...
View All ACB News